Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
 Annual Conference - EconoTimes)
CAMBRIDGE, Mass., April 06, 2016 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a central organ for devastating rare diseases, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will deliver a presentation titled, “Developing an AAV Pipeline and Building a Successful Biotech,” during the BSGCT Annual Conference – AAV in 2016: Biology, vector design and implementation into human gene therapy. The conference will take place at the University College London Institute of Child Health on Friday, April 15, 2016. Dr. Jenkins’ presentation will begin at 1:45pm BST.
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 [email protected] Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 [email protected]
